Ryan D Niederkohr1, I Ross McDougall. 1. Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Room H-0101, Stanford, CA 94305-5281, USA.
Abstract
PURPOSE: Recombinant human TSH (rhTSH) is used to increase radioiodine uptake during imaging of thyroid cancer, obviating the need to render the patient hypothyroid. We assessed the reproducibility of radioiodine uptake, serum thyrotropin (TSH), and stimulated serum thyroglobulin (Tg) levels after rhTSH administration. METHODS: A retrospective review was performed of patients at Stanford who underwent whole-body (131)I scanning for surveillance of thyroid cancer twice after thyroidectomy and (131)I ablation, with rhTSH prior to each scan. Forty-eight hour radioiodine uptake, peak serum TSH, and stimulated serum Tg levels for each study were recorded. Paired t tests and correlation analysis were used to assess interexamination repeatability. RESULTS: Twenty-three patients underwent two scintiscans with rhTSH, for a total of 46 exams. There was no significant difference between percent uptake at 48 h in the paired exams (p=0.40). Serum TSH level was measured in 45 of 46 exams; TSH exceeded 50 mIU/l in all cases, and there was no significant difference between paired TSH levels (p=0.93). All patients had stimulated serum Tg levels measured, with no significant difference between paired Tg levels (p=0.40); after excluding one patient whose Tg changed from 15.8 ng/ml to undetectable between scans without interval treatment, the p value rose to 0.95. There was a strong correlation among paired uptake values (r=0.85, p<0.0001), peak serum TSH (r=0.69, p=0.0003), and stimulated Tg levels (r=0.81, p<0.0001). No discordant scan interpretations were reported. CONCLUSION: Forty-eight hour radioiodine uptake, peak serum TSH, and stimulated serum Tg levels after administration of rhTSH are repeatable between studies, demonstrating reproducibility of diagnostic results without rendering patients hypothyroid.
PURPOSE: Recombinant humanTSH (rhTSH) is used to increase radioiodine uptake during imaging of thyroid cancer, obviating the need to render the patienthypothyroid. We assessed the reproducibility of radioiodine uptake, serum thyrotropin (TSH), and stimulated serum thyroglobulin (Tg) levels after rhTSH administration. METHODS: A retrospective review was performed of patients at Stanford who underwent whole-body (131)I scanning for surveillance of thyroid cancer twice after thyroidectomy and (131)I ablation, with rhTSH prior to each scan. Forty-eight hour radioiodine uptake, peak serum TSH, and stimulated serum Tg levels for each study were recorded. Paired t tests and correlation analysis were used to assess interexamination repeatability. RESULTS: Twenty-three patients underwent two scintiscans with rhTSH, for a total of 46 exams. There was no significant difference between percent uptake at 48 h in the paired exams (p=0.40). Serum TSH level was measured in 45 of 46 exams; TSH exceeded 50 mIU/l in all cases, and there was no significant difference between paired TSH levels (p=0.93). All patients had stimulated serum Tg levels measured, with no significant difference between paired Tg levels (p=0.40); after excluding one patient whose Tg changed from 15.8 ng/ml to undetectable between scans without interval treatment, the p value rose to 0.95. There was a strong correlation among paired uptake values (r=0.85, p<0.0001), peak serum TSH (r=0.69, p=0.0003), and stimulated Tg levels (r=0.81, p<0.0001). No discordant scan interpretations were reported. CONCLUSION: Forty-eight hour radioiodine uptake, peak serum TSH, and stimulated serum Tg levels after administration of rhTSH are repeatable between studies, demonstrating reproducibility of diagnostic results without rendering patientshypothyroid.
Authors: Pamela R Schroeder; Bryan R Haugen; Furio Pacini; Christoph Reiners; Martin Schlumberger; Steven I Sherman; David S Cooper; Kathryn G Schuff; Lewis E Braverman; Monica C Skarulis; Terry F Davies; Ernest L Mazzaferri; Gilbert H Daniels; Douglas S Ross; Markus Luster; Mary H Samuels; Bruce D Weintraub; E Chester Ridgway; Paul W Ladenson Journal: J Clin Endocrinol Metab Date: 2006-01-04 Impact factor: 5.958
Authors: P W Ladenson; L E Braverman; E L Mazzaferri; F Brucker-Davis; D S Cooper; J R Garber; F E Wondisford; T F Davies; L J DeGroot; G H Daniels; D S Ross; B D Weintraub Journal: N Engl J Med Date: 1997-09-25 Impact factor: 91.245